Follicular lymphoma

8 · 20 / page

Ask MedXY AI

Latest news

Tag

Hematology-Oncologydiagnosis-to-treatment intervalFollicular lymphoma

Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy

By MedXY|Jun 30, 2026

Shorter diagnosis-to-treatment intervals independently predict worse outcomes in follicular lymphoma treated with immunochemotherapy, highlighting a novel prognostic factor beyond existing risk indices.

Baseline Circulating Tumor DNA as a Prognostic Biomarker in Untreated Follicular Lymphoma: Insights from the GALLIUM Trial

Hematology-OncologyctDNAFollicular lymphoma

Follicular lymphoma

Latest news

Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy

Baseline Circulating Tumor DNA as a Prognostic Biomarker in Untreated Follicular Lymphoma: Insights from the GALLIUM Trial

Lenalidomide-Rituximab vs. Lenalidomide-Rituximab-Bendamustine in Relapsed/Refractory Follicular Lymphoma: A Phase II Showdown

Challenging the Incurability Paradigm: 15-Year Data Suggests a Cure for Advanced Follicular Lymphoma

Tafasitamab Plus R2 Regimen Sets a New Benchmark for Relapsed or Refractory Follicular Lymphoma: Insights from the inMIND Trial

Epcoritamab Plus R2 Redefines the Standard of Care in Relapsed or Refractory Follicular Lymphoma: Insights from the EPCORE FL-1 Trial

Five-Year ZUMA-5 Follow-Up: Durable Remissions and Potential for Cure with Axicabtagene Ciloleucel in Relapsed/Refractory Follicular Lymphoma

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma